Brief: Immunovia Announces Results From Immray PanCan-D Optimization Work

Immunovia AB (publ)

03/06/2019 14:05

June 3 (Reuters) - Immunovia AB (publ)  IMMNOV.ST :
    * IMMUNOVIA ANNOUNCES EXCELLENT RESULTS ACROSS ALL SYMPTOMATIC RISK GROUPS FROM
IMMRAY PANCAN-D
OPTIMIZATION WORK
    * IMMRAY PANCAN-D BLOOD-BASED TEST FOR EARLY DETECTION OF PANCREATIC CANCER NOW SET FOR Q3
2020
LAUNCH
    * OPTIMIZATION WORK FOR COMMERCIAL VERSION OF IMMRAY PANCAN-D BEEN SUCCESSFUL AND
SIGNIFICANTLY
IMPROVED PERFORMANCE OF TEST
    * TEST NOW SHOWS ACCURACIES HIGHER THAN 90% AND EVEN UP TO 98% IN DIFFERENTIATING PDAC OF
STAGE I
THROUGH IV VERSUS LARGE SYMPTOMATIC RISK GROUPS

Source text for Eikon:  ID:nWkr3bvDS2 
Further company coverage:  IMMNOV.ST 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))